Sangamo Therapeutics (SGMO) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Price: $0.18 --0%
Financial Fact:
Loss from operations: -19.21M
Today's EPS Names:
SMXT, NRIX, VFS, More
Financial Fact:
Loss from operations: -19.21M
Today's EPS Names:
SMXT, NRIX, VFS, More
Join SI Premium – FREE
Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $7.55 million versus the consensus estimate of $10.32 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta Platforms' (META) Zuckerberg Hints New AI Model Ready
- Adnoc Logistics In Talks To Buy Stake In HEA - WSJ
- Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
